Other Information.
+Added: Director and executive officer trading arrangements
+Added: The following table provides information concerning Rule 10b5-1 trading arrangements adopted during the three months ended June 30, 2026, by any director or any executive officer who is subject to the filing requirements of Section 16 of the Securities Exchange Act of 1934.
+Added: These trading arrangements are intended to satisfy the affirmative defense of Rule 10b5-1(c).
+Added: No non-Rule 10b5-1 trading arrangements were adopted by any director or executive officer during the second quarter of 2026.
+Added: In addition, no Rule 10b5-1 or non-Rule 10b5-1 trading arrangements were terminated by any director or executive officer in the second quarter of 2026.
+Added: Name Title Adoption Date Duration (a)
+Added: Number of shares to be sold
+Added: Mark Strobeck President and CEO 5/19/2026 10/1/2026 - 7/3/2028 12,250
+Added: (a) Subject to compliance with Rule 10b5-1, duration could cease earlier than the final date shown above to the extent that the aggregate number of shares to be sold under the trading arrangement have been sold.
The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, which Exhibit Index is incorporated herein by reference.
EXHIBIT INDEX
+Added: 3.1 Certificate of Amendment to the Certificate of Incorporation of Rockwell Medical, Inc.
+Added: (incorporated by reference to the Company's Form 8-K filed on June 29, 2026).
31.1* Certification pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934
8 unchanged sentences
101.PRE* XBRL Taxonomy Extension Presentation Linkbase
−Removed: 104* The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, formatted in Inline XBRL (included as Exhibit 101)
+Added: 104* The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, formatted in Inline XBRL (included as Exhibit 101)
* Filed herewith
2 unchanged sentences
ROCKWELL MEDICAL, INC.
−Removed: May 7, 2026 /s/ Mark Strobeck
+Added: August 13, 2026 /s/ Mark Strobeck, Ph.D.
Mark Strobeck, Ph.D.
1 unchanged sentence
(Principal Executive Officer)
+Added: /s/ Jesse Neri
+Added: Senior Vice President and Chief Financial Officer
+Added: (Principal Financial Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.